Cancer of the colon and rectum (CRC) is the third most common cancer in men and the second most common in women with 1,340,000 new diagnoses worldwide [1] and is therefore considered one of the most life-threatening and common neoplastic diseases all over the world [2].Asia contributes with the highest rate (1,009,400/52.3% of incident cases and 506,499/54.2% of deaths in 2020). In the United States, in the same year, there were about 104,610 new cases of colon cancer and 43,340 patients affected by rectal cancer [3]. According to the AIOM (Italian Association of Medical Oncology) registry, there were approximately 43,700 new diagnoses in Italy in 2020 (men 23,400; women 20,300) [4]. In terms of mortality, 21,700 deaths were expected in Italy in 2021 (men 11,500; women 10,200). Disease-free survival at 5 years from diagnosis is 65% and 66% in men and in women, respectively [4]. The relative cumulative survival rate following a diagnosis of CRC is 64% at 5 years and 58% at 10 years. Stage at diagnosis remains the most important predictor of CRC survival. The 5-year survival rate is 90% for the 39% of patients diagnosed with localized-stage